Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $34 | $2 | $0 |
| % Growth | -100% | 1,576.8% | 5,800% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $1 |
| Gross Profit | -$0 | $33 | $1 | -$1 |
| % Margin | – | 98.9% | 48% | -2,638.2% |
| R&D Expenses | $21 | $20 | $15 | $19 |
| G&A Expenses | $15 | $8 | $7 | $8 |
| SG&A Expenses | $15 | $8 | $7 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $35 | $28 | $21 | $27 |
| Operating Income | -$36 | -$28 | -$19 | -$27 |
| % Margin | – | -84.1% | -966.6% | -78,567.6% |
| Other Income/Exp. Net | $2 | $1 | $2 | $1 |
| Pre-Tax Income | -$34 | -$27 | -$18 | -$25 |
| Tax Expense | -$0 | $1 | -$0 | -$0 |
| Net Income | -$34 | -$28 | -$17 | -$25 |
| % Margin | – | -83.8% | -860% | -74,044.1% |
| EPS | -0.4 | -0.39 | -0.25 | -0.38 |
| % Growth | -2.6% | -56% | 34.2% | – |
| EPS Diluted | -0.4 | -0.39 | -0.25 | -0.38 |
| Weighted Avg Shares Out | 84 | 73 | 69 | 66 |
| Weighted Avg Shares Out Dil | 84 | 73 | 69 | 66 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $2 | $3 | $2 |
| Interest Expense | $2 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$32 | -$25 | -$18 | -$24 |
| % Margin | – | -74.9% | -920% | -70,002.9% |